Study guide

10.2 Melanoma, Mesenchymal, and Neuroendocrine Markers

ASCP Qualification in Immunohistochemistry QIHC

Track your progress as you read

Finished sections get a check mark.

1 Introduction and Exam Overview

1.1 Current QIHC Exam Facts 1.2 Eligibility, CMP, and How to Use This Guide

2 Detection Systems: Immunofluorescence, Enzymes, and Chromogens

2.1 Immunofluorescence Detection 2.2 Detection Enzymes 2.3 Chromogens and Substrates 2.4 Dual-Chromogen and Multiplex Detection

3 Detection Systems: Blocking, Polymer, and Amplification

3.1 Endogenous Enzyme Blocking 3.2 Biotin and Protein Blocking 3.3 Polymer and Multimer Detection 3.4 Amplification Systems

4 Specimen Handling: Fixation, Processing, and Microtomy

4.1 Fixation for IHC 4.2 Tissue Processing 4.3 Microtomy and Slide Preparation

5 Specimen Handling: Cytology, Immunofluorescence, and Frozen Sections

5.1 Cytology Specimens for IHC 5.2 Immunofluorescence Specimens 5.3 Frozen Sections

6 Epitope Enhancement and Antigen Retrieval

6.1 HIER Chemistry and Buffer Systems 6.2 HIER Equipment and Protocols 6.3 Enzyme-Induced Epitope Retrieval 6.4 Combined Retrieval and Optimization

7 Staining Principles and General Immunology

7.1 Antibodies: Structure, Classes, Monoclonal versus Polyclonal 7.2 Antigens and Epitopes 7.3 Direct and Indirect Methods 7.4 Avidin-Biotin Methods

8 Polymer Methods, In Situ Hybridization, and Staining Reagents

8.1 Polymer and Multimer Staining Methods 8.2 In Situ Hybridization (FISH, CISH, SISH) 8.3 Antibody Formats and Titration 8.4 Diluents and Staining Reagents

9 Tissues: Morphology, Cytokeratins, Organ Markers, and Microorganisms

9.1 Morphology, Anatomy, and Basic Pathology 9.2 Cytokeratin Profiling and CUP Patterns 9.3 Organ-Specific Epithelial Markers 9.4 Infectious IHC and Microorganisms

10 Lineage Markers and Preliminary Screening

10.1 Hematolymphoid Markers 10.2 Melanoma, Mesenchymal, and Neuroendocrine Markers 10.3 Preliminary Screening and Expected Patterns

11 Staining Troubleshooting and Mounting

11.1 Staining Troubleshooting 11.2 Mounting Procedures

12 Quality Control, Controls, and Analytic Validation

12.1 Documentation, Lots, Slide Storage, and Personnel 12.2 Control Tissue Selection and Use 12.3 Method Selection, Optimization, and CAP Analytic Validation 12.4 Operational Troubleshooting

13 Safety, Laboratory Mathematics, Equipment, and Regulations

13.1 Laboratory Safety 13.2 Laboratory Mathematics 13.3 Ancillary Equipment and Automated Stainers 13.4 Regulations: Federal Government and Accrediting Agencies

10.2 Melanoma, Mesenchymal, and Neuroendocrine Markers

Key Takeaways Explain This Topic AI

S100 is nuclear plus cytoplasmic and sensitive but not specific; SOX10 is nuclear and a tighter melanocytic/nerve-sheath screen; Melan-A/MART-1 and HMB-45 are cytoplasmic melanosome-associated stains that are often negative in desmoplastic melanoma.

PRAME is a nuclear stain used at a practical level to support melanoma versus many nevi; it is not 100% in either direction and is not a substitute for morphology.

Desmin and SMA are cytoplasmic muscle stains; myogenin is nuclear and the rhabdomyosarcoma-direction marker—do not treat SMA-positive myofibroblasts as skeletal muscle.

Beta-catenin is a pattern example: membranous in most epithelia, nuclear (often with cytoplasm) when the Wnt complex is disrupted, as in desmoid-type fibromatosis; cytoplasmic blush without the expected compartment is not a diagnosis.

Synaptophysin, chromogranin, nuclear INSM1, and membrane CD56 are neuroendocrine screens with different specificity; a keratin-poor epithelioid tumor is not automatically a true sarcoma.

Last updated: September 2026

10.2 Melanoma, Mesenchymal, and Neuroendocrine Markers

Quick Answer: Melanoma screens: S100 (nuclear and cytoplasmic), SOX10 (nuclear), Melan-A/MART-1 and HMB-45 (cytoplasmic), PRAME (nuclear, practical melanoma-versus-nevus use). Muscle: cytoplasmic desmin and SMA; nuclear myogenin for skeletal-muscle differentiation. Beta-catenin: membranous versus nuclear as a Wnt-pathway pattern example. Neuroendocrine: synaptophysin, chromogranin, nuclear INSM1, membrane CD56. A keratin-poor epithelioid tumor is not automatically a true sarcoma. Chapter 9 already taught CK7/CK20 maps—do not reuse them here.

This ExamFinch section is independent teaching on melanoma, mesenchymal, and neuroendocrine staining patterns covering published QIHC staining topic IV.B.2.a. It is not an ASCP publication and does not claim Board, CAP, or WHO-classification approval. Clones named below are examples. These panels are lineage screens, not diagnoses.

Melanocytic markers at practical QIHC level

Melanoma can mimic carcinoma, lymphoma, and sarcoma. The first job is still the H&E (pigment versus chromogen, nesting versus sheets, nucleoli). Then use melanocytic antibodies in their expected compartments .

Marker Expected compartment Practical screening use Everyday limit

S100 Nuclear and cytoplasmic Sensitive melanocytic and nerve-sheath screen; also dendritic cells, cartilage, some carcinomas Positive does not equal melanoma

SOX10 Nuclear Tighter melanocytic and Schwannian screen than S100 Still not melanoma-specific; some other tumors label

Melan-A / MART-1 Cytoplasmic Supports melanocytic differentiation in epithelioid melanoma Often negative in desmoplastic melanoma; adrenal cortex and some PEComas can label

HMB-45 (gp100) Cytoplasmic (melanosomes) More specific melanosome marker in many epithelioid melanomas Less sensitive; desmoplastic melanoma often negative

PRAME Nuclear Practical support for melanoma versus many benign nevi Neither 100% sensitive nor 100% specific; morphology still rules

S100 must show nuclear staining to count as a real S100 result; cytoplasmic-only S100 is not the textbook melanocytic pattern. Because S100 is promiscuous (nerve, cartilage, Langerhans cells, some carcinomas, some histiocytic lesions), a positive S100 starts a panel; it does not finish one.

SOX10 is the nuclear transcription-factor screen many laboratories now lead with for suspected melanoma and nerve-sheath tumors. Nuclear localization is required. SOX10-positive spindle cells in a scar-like dermis raise desmoplastic melanoma and scar/nerve-sheath differentials together—Melan-A and HMB-45 often will not rescue you there.

Melan-A (MART-1) and HMB-45 are cytoplasmic. They are useful in epithelioid melanoma and in confirming melanocytic differentiation when S100/SOX10 are positive. Desmoplastic melanoma is the classic HMB-45-negative / Melan-A-negative (or only focal) pitfall: S100 and SOX10 remain the workhorse stains. Do not call a SOX10-positive desmoplastic tumor “not melanoma” because HMB-45 is negative.

PRAME (preferentially expressed antigen in melanoma) is nuclear . At a practical screening level, many melanomas are PRAME-positive and many banal nevi are PRAME-negative. Exceptions exist: some melanomas are PRAME-negative; some nevi (including some dysplastic or traumatized lesions) can show labeling. Teach PRAME as supportive nuclear context , not as a yes/no melanoma assay and not as a replacement for a dermatopathologist’s threshold.

Pigment versus chromogen: coarse brown-black melanin is already on the H&E. Use a red chromogen or a bleach protocol when brown DAB and melanin collide. Section 9.1 already taught pigment traps; the same rule applies here.

Mesenchymal muscle markers: desmin, SMA, myogenin

When the H&E looks like muscle or a spindle-cell sarcoma, the usual IHC trio is desmin , smooth-muscle actin (SMA) , and myogenin —read in the correct compartment.

Desmin is a muscle intermediate filament , cytoplasmic . It marks skeletal, cardiac, and many smooth-muscle cells, and it is the expected stain in rhabdomyosarcoma and leiomyosarcoma. Desmin also labels some myofibroblasts and some non-muscle tumors; it is a muscle-class stain, not a sarcoma stamp.

SMA is cytoplasmic (often membrane-accentuated). It marks smooth muscle and myofibroblasts. A healing biopsy site full of SMA-positive myofibroblasts is not leiomyosarcoma. Vascular smooth muscle in vessel walls is the usual internal control; do not score the artery and call the tumor positive.

Myogenin is nuclear . It indicates skeletal-muscle differentiation and is the marker that points toward rhabdomyosarcoma in the small-round-cell and spindle-cell differentials. Cytoplasmic myogenin is not a rhabdomyosarcoma call. Leiomyosarcoma is typically myogenin-negative (desmin/SMA-positive). MyoD1 is a related nuclear skeletal-muscle factor used in some panels; if you see it, still score nuclei.

  • Antibody Compartment Points toward Screening pitfall
  • Desmin Cytoplasmic Muscle (skeletal or smooth) Myofibroblasts; do not skip morphology
  • SMA Cytoplasmic Smooth muscle / myofibroblasts Biopsy-site myofibroblasts; vessel walls as false “tumor”

Myogenin Nuclear Skeletal-muscle differentiation (rhabdomyosarcoma direction) Cytoplasmic blush; treating SMA-positive spindles as rhabdomyosarcoma

Beta-catenin as a nuclear-versus-cytoplasmic pattern example

Beta-catenin is not a melanoma stain. It is taught here because QIHC staining-pattern content includes reading compartment , and beta-catenin is a clean teaching example of membranous versus nuclear signal with different meaning.

In most epithelia, beta-catenin sits at the adherens junction : expected stain is membranous (often with a little cytoplasm). When the Wnt destruction complex is disrupted (CTNNB1 mutation or equivalent), beta-catenin accumulates in the nucleus . Desmoid-type fibromatosis is the mesenchymal example: look for nuclear beta-catenin in the spindle cells (often not every nucleus). Many colorectal carcinomas and some other tumors also show nuclear beta-catenin—this section is not a GI atlas.

Screening rules:

Membranous beta-catenin in epithelium is the default physiologic pattern, not a “positive special stain.”

Nuclear labeling (usually with cytoplasm) is the abnormal Wnt-type pattern the pathologist wants documented.

Cytoplasmic-only blush without membrane or nucleus is not a desmoid call and is often noise or a titer problem.

Endothelium and some normal cells can show weak nuclear staining—compare with the tumor spindles, do not over-call a vessel.

If a stem describes nuclear beta-catenin in a deep fibromatosis-like proliferation, name nuclear localization . If it describes crisp membranes in benign colonic epithelium, that is the normal pattern, not disease.

Neuroendocrine markers: synaptophysin, chromogranin, INSM1, CD56

Neuroendocrine (NE) IHC supports NE differentiation; it does not by itself prove a primary organ. Poorly differentiated NE carcinomas can be keratin-pale or keratin-dot-like (Chapter 9 taught keratin localization; this section does not reprint coordinate CK tables).

  • Marker Compartment Practical character
  • Synaptophysin Cytoplasmic Sensitive NE screen; can be weaker in high-grade NE carcinoma

Chromogranin A Cytoplasmic (dense-core granules) More specific, often less sensitive; high-grade NE carcinoma may be chromogranin-poor

  • INSM1 Nuclear NE transcription factor; tighter than CD56 for NE differentiation
  • CD56 (NCAM) Membrane Sensitive, not specific (NK cells, some thyroid, some rhabdomyosarcomas, others)

Synaptophysin is the usual sensitive cytoplasmic screen. Chromogranin is the more specific granule marker and may be negative when the tumor is poorly granulated. INSM1 is scored in nuclei ; it has become the preferred NE transcription-factor stain in many laboratories because it is less promiscuous than CD56. CD56 is a membrane stain that will light up true NE tumors and many non-NE mimics—do not diagnose neuroendocrine carcinoma on CD56 alone.

Normal islets, pulmonary NE cells, or adrenal medulla (depending on the control tissue) are internal or external controls. A completely negative NE panel with negative internal NE cells is a failed stain, not proof the tumor is “non-NE.”

Keratin-poor tumors versus true sarcoma

Chapter 9 covered pan-keratins and CK7/CK20 coordinate maps. Do not reprint those tables. The screening idea that still belongs here:

Absence of keratin does not equal sarcoma. Adrenal cortical carcinoma, some hepatocellular carcinomas, some sarcomatoid carcinomas, and some melanoma and hematolymphoid tumors are keratin-poor or keratin-negative. Presence of keratin does not equal carcinoma in every spindle-cell tumor: synovial sarcoma and epithelioid sarcoma are classic keratin-positive mesenchymal tumors.

A practical first-line frame after H&E:

Broad keratin (already discussed in Chapter 9) plus CD45 plus SOX10/S100—carcinoma versus hematopoietic versus melanoma screens.

If those are negative and the tumor looks mesenchymal, add muscle markers (desmin/SMA/myogenin) and other directed stains the pathologist orders (not a fishing expedition of every sarcoma antibody).

If the tumor looks neuroendocrine, add synaptophysin/chromogranin/INSM1 rather than calling it sarcoma because keratin is faint.

True sarcoma is a morphology-plus-panel diagnosis. The QIHC technologist’s job is to produce interpretable lineage stains in the right compartment with working controls, not to issue “undifferentiated sarcoma” from a single negative keratin.

Worked example

A dermal spindle-cell tumor in sun-damaged skin is HMB-45-negative and Melan-A-negative. S100 and SOX10 are strongly nuclear (S100 also cytoplasmic) in the spindles. PRAME shows nuclear labeling in a subset. SMA highlights only vessel walls; desmin and myogenin are negative; keratin is negative. That cluster is a desmoplastic-melanoma-type melanocytic pattern , not “not melanoma because HMB-45 is negative,” and not a myofibroblastic sarcoma because SMA is present in vessels. A second case, a deep abdominal wall mass, shows SMA and desmin in cytoplasm of long fascicles, myogenin-negative nuclei, and nuclear beta-catenin in a fraction of spindles: document nuclear beta-catenin as a desmoid-type Wnt pattern for the pathologist—do not call it melanoma because S100 was not even indicated. A third case, a lung mass with salt-and-pepper chromatin, is CD56-positive but INSM1-negative, synaptophysin-negative, chromogranin-negative, with CD56 also staining lymphocytes: do not sign out neuroendocrine carcinoma on CD56 alone.

Lineage markers are pattern tools under topic IV.B.2.a. They feed the pathologist’s diagnosis; they are not the diagnosis.

Loading diagram... Lineage screens: melanocytic, muscle, Wnt pattern, neuroendocrine